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Background: Muscle wasting is a hallmark of many chronic conditions but also of aging and results in a
progressive functional decline leading ultimately to disability. Androgens, such as testosterone were proposed as
therapy to counteract muscle atrophy. However, this treatment is associated with potential cardiovascular and
prostate cancer risks and therefore not acceptable for long-term treatment. Selective Androgen receptor modulators
(SARM) are androgen receptor ligands that induce muscle anabolism while having reduced effects in reproductive
tissues. Therefore, they represent an alternative to testosterone therapy. Our objective was to demonstrate the activity
of SARM molecule (GLPG0492) on a immobilization muscle atrophy mouse model as compared to testosterone
propionate (TP) and to identify putative biomarkers in the plasma compartment that might be related to muscle
function and potentially translated into the clinical space.
Methods: GLPG0492, a non-steroidal SARM, was evaluated and compared to TP in a mouse model of hindlimb
immobilization.
Results: GLPG0492 treatment partially prevents immobilization-induced muscle atrophy with a trend to promote
muscle fiber hypertrophy in a dose-dependent manner. Interestingly, GLPG0492 was found as efficacious as TP
at reducing muscle loss while sparing reproductive tissues. Furthermore, gene expression studies performed
on tibialis samples revealed that both GLPG0492 and TP were slowing down muscle loss by negatively
interfering with major signaling pathways controlling muscle mass homeostasis. Finally, metabolomic profiling
experiments using 1H-NMR led to the identification of a plasma GLPG0492 signature linked to the modulation
of cellular bioenergetic processes.
Conclusions: Taken together, these results unveil the potential of GLPG0492, a non-steroidal SARM, as treatment for,
at least, musculo-skeletal atrophy consecutive to coma, paralysis, or limb immobilization.
Keywords: Selective androgen receptor modulator, Immobilization, Muscle wasting, AnabolismBackground
Maintenance of skeletal muscle mass is mainly achieved
by a homeostatic balance between muscle regeneration,
protein synthesis and protein degradation. This tight bal-
ance is significantly altered during aging, leading to muscle
wasting coupled to a decline in function over time named
sarcopenia [1]. In addition, skeletal muscle atrophy occurs
in many chronic conditions such as cancer cachexia, sep-
sis, diabetes, renal failure and arthritis [2,3]. Mechanistic* Correspondence: philippe.clement-lacroixl@glpg.com
GALAPAGOS SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
© 2014 Blanqué et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.studies performed in rodent models of muscle atrophy
as well as in patients revealed that atrophy is an active
process regulated by specific signaling pathways and tran-
scriptional programs (See [4] for review). Clusters of genes
similarly up or down-regulated in the atrophied muscle
under various conditions are referred as atrogenes [5].
The rapid induction of the muscle-specific ubiquitin li-
gases, MAFbx/atrogin-1 and muscle ring finger 1 (MurF1)
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Atrogin-1 or MurF1 were shown to be resistant to some ex-
tent to denervation induced atrophy [6]. Finally, Atrogin-1
and MurF1 were reported to be involved in the degradation
of both regulatory and structural proteins including MyoD,
Calcineurin A and myosin, respectively [9-12]. In addition
to the Ubiquitin-proteasome pathway, autophagy has also
been shown as a major signal activated at the transcrip-
tional level and leads to protein catabolism (See [4] for re-
view). The lysosome proteases, Cathepsin-L and LC3-II
were reported to be increased in rodent models of muscle
atrophy [13,14]. FoxOs have been identified as key tran-
scription factors at the crossroads of both protein break-
down via the regulation of Atrogin-1 and MurF1 gene
transcription [8,15] and protein synthesis via the regula-
tion of 4EBP1 and the subsequent inhibition of the mTOR
signaling pathway [16]. Disruption of the subtle balance
between protein synthesis and degradation during muscle
atrophy involves the suppression of bioenergetic pathways
associated to mitochondrial functions and controlled by
PGC-1α whose expression is sharply reduced in various
models of muscle wasting [17-19].
Despite our growing understanding of the molecular
mechanisms controlling muscle atrophy, there is still an
unmet need for therapies that prevent or reverse muscle
atrophy resulting into a significant improvement of phys-
ical function in patients. A large number of studies have
established the beneficial impact of androgen treatment on
both muscle mass and strength [20,21]. Androgens control
a broad spectrum of physiological processes mainly via the
nuclear androgen receptor (AR), a member of the nuclear
receptor super-family [22]. However, treatment with an-
drogens such as testosterone is associated with potential
cardiovascular and prostate cancer risks [23]. Furthermore,
alteration of circulating levels of androgens or modu-
lation in receptor function lead to multiple disorders such
as hypogonadism, muscle wasting, cachexia, osteoporosis,
loss of reproductive functions and prostate cancers [23].
Selective androgen receptor modulator (SARM), synthetic
compounds designed to demonstrate tissue-specific action
for muscle and bone represent an alternative to testoster-
one therapy (See [24,25] for review). We recently identified
GLPG0492 as a non-steroidal SARM [26]. This molecule
displays an excellent selectivity profile (>500-fold in bind-
ing assays) versus members of the steroid receptor family
and behaves as a partial AR agonist in cell-based assays
[26]. GLPG0492 has been previously tested in a standard
castrated male rodent model in which it demonstrated
after oral dosing robust anabolic activity on levator ani
(LA) muscle comparable to testosterone propionate,
but dissociated from the androgenic activity on ventral
prostate. The dose displaying 50% activity on LA was
0.75 mg/kg/day, while at the maximum 30% activity can
be achieved on prostate at the highest dose tested [27].So, GLPG0492 has demonstrated a robust selectivity
for muscle versus prostate, as SARM [26,27].
To determine the therapeutic potential of GLPG0492 for
muscle wasting-associated diseases, we evaluated this com-
pound in a mouse model of hindlimb immobilization and
compared its effects to testosterone propionate as refer-
ence. In this model, GLPG0492 attenuated the loss of
muscle mass induced by immobilization by reducing, at
least in part, fiber atrophy. Furthermore, gene expression
studies revealed that GLPG0492 negatively antagonized
transcriptional programs induced by immobilization. Fi-
nally we look for a metabolomic signature which might be
considered as a bona fide biomarker of target engagement
in future clinical studies. Taken together, these results re-
vealed the potential of GLPG0492 as treatment for disuse
(e.g. coma, paralysis, hospitalization, limb immobilization).
Methods
Reagents
GLPG0492 was synthesized by the medicinal chemistry
department at Galapagos and was determined to be >99%
pure by HPLC and/or NMR analysis [26]. Testosterone
proprionate was purchased from Sigma (France). Dosing
solutions of GLPG0492 and TP were prepared as solu-
tions in a vehicle of 5% Ethanol and 95% Corn oil.
Animal studies
Experimental protocols were approved by the Galapagos
Institutional Animal Care and Use Committee. Male BALB/
cj mice (10 weeks old; n = 10/group, Janvier Labs) main-
tained on a standard chow diet, were subjected to unilateral
hindlimb plaster casting (day 0) as previously described [28].
Intact or immobilized mice were treated for 7 days with
increasing doses of GLPG0492 (0.3, 3 and 10 mg/kg/d) or
testosterone-propionate (TP: 1 mg/kg/d) or vehicle (5%
Ethanol/95% Corn oil) by subcutaneous administration.
At the end of the treatment period (5 h after the last dose),
mice were sacrificed by decapitation and blood was recov-
ered for serum preparation. Gastrocnemius and tibialis
from both immobilized and contralateral legs were col-
lected, weighed, and snap-frozen in liquid nitrogen.
Bio-analysis
Blood samples were collected in lithium heparinate-containing
vials in order to prepare serum samples. Serum testoster-
one levels were evaluated at day 7 in each group using a
RIA kit (Orion Diagnostica, Finland). In addition, circu-
lating levels of GLPG0492 were quantified at steady-state
at 3 or 5 h post-dose by LC-MS/MS in Galapagos bio-
analytical department.
RNA analysis
Total RNA was extracted from tibialis using Qiagen RNA
extraction kits following manufacturer’s instructions. Total
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USA) at 37°C for 30 minutes, followed by inactivation at
75°C for 5 minutes. Real time quantitative PCR (RT-QPCR)
assays were performed using an Applied Biosystems
ViiA7 sequence detector. Total RNA (1 μg) was reverse
transcribed with random hexamers using Taqman reverse-
transcription reagents kit (Applied Biosystems) following
the manufacturer’s protocol. Gene expression of Atrogin-1,
MurF1, IGF1, LC3, FoxO1, IL1β, Myogenin, and PGC1α
and PGC1α4 levels were determined by Sybr green
assays [29]. Atrogin-1, MurF1, IGF1, LC3, FoxO1, IL1β,
Myogenin, PGC1α, PGC1α4 isoform were detected using
QuantiTect Primer Assays (Qiagen) while PGC1α4
isoform was detected using forward and reverse primers
describe by Ruas and coworkers [30]. GAPDH transcript
was used as an internal control to normalize the variations
for RNA amounts. Gene expression levels are expressed
relative to GAPDH mRNA levels. All the results presented
are expressed as mean ± S.E.M. All the primers used in
this study and Ct values are available upon request.
Tissue weighing and fiber cross-sectional area (FCSA)
determination
At sacrifice, tibialis and prostate were collected and weighed.
Muscles were subsequently snap-frozen in liquid ni-
trogen. Cryo-sections (10 μm thick) were prepared from
the mid-gastrocnemius using a cryostat (Microm) and
fixed in formalin for one minute prior assayed with a
double immunochemistry IHC as following: sections were
probed simultaneously for 30 minutes with a mouse anti-
Myosin light chain (Clone NOQ, Abcam) and a rabbit
anti-laminin antibody using an autostainer (Dako). Sec-
ondary antibodies were anti-mouse-fluorescein and anti-
rabbit-dye light, respectively. Laminin IHC provided a
fluorescent staining of the border of all fibers and myosin
light-chain IHC gave a fluorescent stain of slow-twitch fi-
bers. Consequently, the fibers only immunostained for
laminin and not for myosin light chain correspond to the
fast-twitch fibers. Histomorphometric analyses were per-
formed using a fluorescent microscope (Objective 20,
Olympus). Two series of images were recorded from two
representative areas containing either fast-twitch only
or both slow and fast-twitch fibers. Morphometric ana-
lyses were performed using the imaging software system
(Sisn’Com, France). For the evaluation of FCSA and fiber-
type distribution, all fibers in each muscle section were
analyzed. For FCSA, fibers were gathered in different
groups according to their range size, and each group was
expressed as a percentage of the total fiber number.
1H-NMR metabolic profiling
Serum samples (obtained at necropsy 5 h post last dose)
were mixed with an equal volume of 3/2 chloroform-D/
Methanol-D4. Following incubation, each sample wascentrifuged at 6,000 rpm for 10 minutes. The upper layer
was recovered and mixed with an internal standard solu-
tion provided by Chenomx (Edmonton, Canada). NMR
spectra were acquired on a Varian INOVA 800 MHz NMR
spectrometer equipped with a Z-gradient HCN 5 mm
cold-probe. The pulse sequence used was 1D-noesy with a
990 ms pre-saturation on water and a 4 s acquisition time.
Spectra were collected with 416 transients and 4 steady-
state scans at 298 K. Spectra were processed and analyzed
using Chenomx NMR suite 7.1.
Statistical analysis
Results are shown as mean ± S.E.M. Data were analyzed
by ANOVA followed by Dunnett’s multiple comparison
tests. Differences with p < 0.05 were considered to be
statistically significant. For FCSA distribution, the rela-
tionship between treatment and FCSA distribution has
been displayed in a contingency table. The differences be-
tween the frequencies of FCSA distribution were tested
by Chi-square test. In addition, ANOVA followed by
Dunnett’s multiple comparison tests have been performed
for each cluster of distribution.
Results & discussion
Skeletal muscle atrophy can be experimentally induced in
rodents using different approaches such as the denerv-
ation [31], tail suspension [32] or cast immobilization
[33]. The anabolic properties of the recently identified
SARM, GLPG0492, were evaluated in the adapted
mouse model of hindlimb immobilization as described by
Okamato and coworkers [28]. In this model, mice are sub-
jected to unilateral hindlimb plaster casting. As expected,
hindlimb immobilization for 7 days resulted in a signifi-
cant loss in muscle mass (−21%, p < 0.001) compared to
intact animals (Figure 1A). TP treatment completely pre-
vented muscle loss at day 7 in line with previous re-
ports [34,35]. Interestingly, GLPG0492 dose-dependently
reduced immobilization-induced gastrocnemius atrophy
with a maximal significant effect observed between 3
and 10 mg/kg/d. After 7 days of treatment, TP induced a
small but significant increase in gastrocnemius weight in
the contralateral leg as compared to intact animals, dem-
onstrating its anabolic properties (Figure 1B). A similar
dose–response was observed in GLPG0492-treated mice
although the difference was found statistically signifi-
cant only at dose 3 mg/kg/d (Figure 1B). Similar re-
sults were obtained in female mice (data not shown).
Dose-dependent effects of GLPG0492 in this model
are in line with its plasma exposure at steady state
(Table 1). These results indicate that GLPG0492, similarly
to TP, is able to reduce skeletal muscle atrophy in the hind-
limb immobilization model in a dose-dependent manner.
It is noteworthy that GLPG0492 efficacy was achieved










































































Figure 1 GLPG0492 reversed immobilization-induced muscle atrophy in a dose-dependent manner. Normalized gastrocnemius weight
from both immobilized (Panel A) and contralateral (Panel B) legs was assessed at day 7 in intact or immobilized mice receiving increasing doses
of GLPG0492 (0.3, 3, 10 mg/kg/day) or TP (1 mg/kg/day) or CTL immobilized (ethanol/corn oil, 5/95 v/v). Panel C: Normalized prostate weight at
day 7, from immobilized mice receiving increasing doses of GLPG0492 (0.3, 3, 10 mg/kg/day) or TP or CTL vehicle (n = 10 per group; #p < 0.05,
##p < 0.01, ###p < 0.001 vs. Intact (white bar); *p < 0.05, **p < 0.01, ***p < 0.001 vs. CTL immobilized (black bar)).
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trast to TP as compared to immobilized control group
(Figure 1C). Finally if body weight loss is observed be-
tween intact group and the whole of immobilized groups
at day 7, nor TP, neither GLPG0492 treatments are able
to counteract this loss (Table 2).
Having established the anabolic properties of GLPG0492
in an experimental model of muscle loss, we next deter-
mined its influence on muscle fibers atrophy. As expected,
7 days of immobilization led to a reduction of both slowTable 1 Plasma GLPG0492 levels in male mice at






mean ± SEM (ng/mL)
0.3 3 8.62 ± 2.33
5 4.78 ± 0.46
3 3 78.8 ± 9.06
5 58.0 ± 7.45
10 3 184.0 ± 15.4
5 512.0 ± 324.5(indicated by a red star) and fast-twitch (indicated by a
white star) fibers diameter as demonstrated by histomor-
phometric analysis (Figure 2A). These results are in line
with previously published reports [28,36,37]. Fibers atro-
phy was similarly modulated by both GLPG0492 (at 10 m/
kg/d) and TP treatments (Figure 2B). Effects obtained with
GLPG0492 tended to be dose-dependent (Figure 2B).
GLPG0492 and TP treatments both modify mean FCSA
and distribution of muscle fibers. Moreover FCSA from
TP and GLPG0492-treated groups were not significantly
different, even though GLPG0492 seems more active on
slow fibers (Figure 2B & 2C).
These results indicate that GLPG0492 partially prevents
immobilization-induced muscle loss by, at least in part,
limiting muscle fiber atrophy. It is noteworthy that both
GLPG0492 and TP affect similarly both slow and fast
twitch muscle fiber in line with previous studies per-
formed in young men [38].
Since skeletal muscle atrophy has clearly been linked to
the activation of various transcriptional programs (See [4]
for review), we next determined the influence of both
GLPG0492 and TP on the expression of key genes previ-
ously identified in experimentally-induced muscle atrophy
Table 2 Serum testosterone levels and body weight evolution in male mice treated for 7 days with increasing doses of
GLPG0492 and TP
Testosterone (nM) Body weight day 0 (gr) Body weight day 7 (gr) % BW increase (d7-d0)
Intact 2.4 ± 0.6 24.3 ± 0.3 25.5 ± 0.3 +5.0%
CTL 1.7 ± 0.3 24.2 ± 0.4 22.5 ± 0.5### −6.8%
GLPG0492 0.3 mg/kg/d 1.9 ± 0.6 24.2 ± 0.2 23.7 ± 0.3### −1.9%
GLPG0492 3 mg/kg/d 2.2 ± 0.8 23.6 ± 0.4 22.9 ± 0.3### −2.3%
GLPG0492 10 mg/kg/d 1.7 ± 0.6 23.8 ± 0.2 23.3 ± 0.3### −2.1%
TP 1 mg/kg/d 3.3 ± 0.5 23.8 ± 0.3 23.4 ± 0.4### −1.6%



































Figure 2 GLPG0492 reduced muscle fibers atrophy induced by hindlimb immobilization. Panel A: representative immuno-fluorescence
staining of gastrocnemius cryosections for myosin light chain and laminin discriminating slow-twitch fibers (red star) from fast-twitch fibers
(white star). TP and GLPG0492 were tested at 1 and 10 mg/kg/day, respectively. Panel B: FCSA was determined at day 7 in intact and immobilized
mice receiving increasing doses of GLPG0492 (0.3, 3, 10 mg/kg/day) or TP (1 mg/kg/day) or CTL vehicle. (n = 10 per group; #p < 0.05, ##p < 0.01,
###p < 0.001 vs. intact; ***p < 0.001 vs. CTL immobilized). Panel C: Cross-sectional area (CSA) of gastrocnemius muscle fast and slow fibers
distribution (n = 10 per group; *p < 0.05, **p < 0.01, ***p < 0.001 vs. CTL immobilized).
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atrophy were found to mainly occur early on in the early
phases (between day 2 and day 7) in both rodent and hu-
man studies [5,17,28,36,40]. Gene expression studies were
performed on tibialis, one of the two intermediary twitch
muscles collected. As expected, casting resulted in a sig-
nificant induction of the expression of the muscle-specific
ubiquitin ligases, Atrogin-1 and MurF1 (Figure 3a). Sur-
prisingly, MurF1, but not Atrogin-1, expression was sig-
nificantly inhibited in response to both GLPG0492 and
TP treatments (Figure 3a). Expression of FoxO1, a tran-
scription factor, controlling atrogene expression and
maintaining the atrophied state [8,15], was also found
up-regulated after 7 days of immobilization. This gene
induction was significantly attenuated in response to
both GLPG0492 and TP treatments. Similarly Myogenin,
a gene encoding a transcription factor known to be in-
creased in atrophied muscles [5,41], was also up-regulated
after 7 days of immobilization and was also repressed by
both GLPG0492 and TP treatments (Figure 3b). Cytokines
including TNFα and IL1β have been shown to be involved
in the pathogenesis of muscle wasting [42]. Here, we
found a very significant induction of IL1β expression (9-
fold) in immobilized versus intact animals in line with
previous findings [39]. Remarkably, this induction was
abolished by GLPG0492 and TP treatments. Finally,
PGC-1α mRNA levels were found to be modestly re-
duced in response to 7 days of immobilization (Figure 3B).
PGC-1α is a transcriptional co-activator that controls the
expression of genes involved in oxidative metabolism and
causes many of the changes associated with endurance
training, including mitochondrial biogenesis, fiber-type
switching, stimulation of fatty acid oxidation, angiogenesis
and resistance to muscle atrophy [43,19]. So, these results
are somehow in contrast with previous reports describing
a profound suppression of PGC-1α expression [5,19,39].
This discrepancy might be explained by the different kin-
etic of analysis. Indeed, PGC-1α gene suppression seems
to reach its peak after 2 to 3 days of immobilization [5]. In
addition, it has been recently described that PGC-1α plays
a role in atrophy through the alternative splice variant
called alpha-4 [30]. Our results shown that expression of
PCG-1α4 variant was not regulated by immobilization at
day 7. It is noteworthy that gene regulations of the two
PGC-1α splice variants, in our model, are small in term of
fold induction Nevertheless, the in PGC-1α expression was
significantly increased whereas PGC1α4 is significantly
decreased by GLPG0492 and TP treatments (Figure 3b).
Taken together, these results suggest that GLPG0492
prevents muscle atrophy in this model by, at least in part,
negatively interfering with different transcriptional pro-
grams related to muscle wasting.
Since skeletal muscle plays a key role in metabolic and
energy homeostasis and since limb immobilization hasbeen shown to profoundly affect bioenergetic pathways
linked to mitochondrial function [17], we next per-
formed a focused metabolomic analysis using 1H-NMR
to capture these metabolic changes in the blood com-
partment and to determine whether GLPG0492 treat-
ment may to some extent affect these alterations of the
metabolome. Furthermore, identified metabolites signifi-
cantly modulated in blood in response to GLPG0492
treatment might be considered as potential biomarkers
of GLPG0492 during clinical development. Using 1H-
NMR, 40 metabolites could be identified and precisely
quantified within these samples (Table 3). The BCAAs are
among the nine essential amino acids for humans, ac-
counting for 35% of the essential amino acids in muscle
proteins and 40% of the preformed amino acids required
by mammals. Although it has been reported that muscle
protein synthesis significantly declined during the first
6 h of immobilization (40), it has also been shown that
immobilization of hindlimb by cast fixation for 1 d in-
creased muscle protein breakdown [44]. Here, our hindlimb
immobilization model led to a notable, but non-significant
reduction in a number of circulating amino acids includ-
ing the so-called branched-chain amino acids (BCAA: iso-
leucine, leucine and valine). BCAA have been shown to
inhibit proteolysis in skeletal muscle [45,46]. These amino
acids provide the amino groups required for synthesis of
glutamine and alanine. Protein degradation in skeletal
muscle results in the release of amino acids, particularly
alanine. But alanine is channeled to the liver for gluco-
neogenesis and APP synthesis, and ALT activity is in-
creased during immobilization, which could explain the
reduced plasma alanine concentration in immobilized ani-
mals [47]. In addition, urocanate, a product derived from
histidine breakdown, was significantly increased in serum
samples from immobilized mice (Table 3).
As in our study, increased of atrogin-1 and MuRF1 pro-
teins have been reported in hindlimb suspension rat
model. L-leucine and the leucine metabolite β-hydroxy-β-
methylbutyrate (Ca-HMB) have been reported to attenuate
the increase in atrogin-1 and MuRF1 proteins in hindlimb
suspension rat model [48]. Another recent paper suggest
that leucine, could down regulate the MurF1 protein in
mouse cachexia model [49]. Nevertheless, in our study,
modulation of BCAAs, especially leucine, by GLPG0492 is
not strong enough to explain the significant gene regula-
tion of MurF1. In fine, GLPG0492 treatment for 7 days did
not significantly alter these changes in amino-acids levels
with one exception being glutamine (Figure 4; Table 3).
Glutamine has been shown to stimulate protein synthesis
and to inhibit protein catabolism in skeletal muscle in vitro
and in vivo [47].
By contrast, GLPG0492 treatment led to a significant
elevation in tricarboxylic acid (TCA) cycle intermediates
















































































































































































































Figure 3 (See legend on next page.)
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Figure 3 GLPG0492 selectively modulated key pathways involved in muscle atrophy. Gene expression levels were monitored at day 7 in
tibialis muscle samples from intact or immobilized mice receiving either GLPG0492 (10 mg/kg/day) or TP (1 mg/kg/day) or vehicle. Figure 3a:
Atrogin-1, MurF1, LC3, IGFI, FoxO1 and Figure 3b: Myogenin, IL1B, PGC-1α (n = 10 per group; ##p < 0.01, ###p < 0.001 vs. Intact; *p < 0.05,
**p < 0.01, ***p < 0.001 GLPG0492-treated vs. CTL immobilized).
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These TCA cycle intermediates were found as part of a
metabolic signature of exercise in human plasma [50] and
clearly point to a modulation of cellular bioenergetic pro-
cesses linked to mitochondrial function. Moreover, ketone
bodies such as 3-hydroxybutyrate, acetate and acetone
were found also to be increased in response to our SARM.
Interestingly, Vega and coworkers reported a similar in-
crease in 3-hydroxybutyrate in adult men in response to a
short-term administration of oxandrolone, a synthetic
testosterone derivative [51]. These authors suggested
that oxandolone induced hepatic ketogenesis. Additional
studies will be required to determine whether GLPG0492-
mediated 3-hydroxybutyrate elevation in this hindlimb
immobilization model is occurring through a similar
mechanism. Finally, O-acetylcarnitine levels were doubled
in response to GLPG0492. This might reflect an increase
in fatty acid oxidation. Interestingly, plasma acetylcarni-
tines were identified as exercise-related biomarkers and to
be essentially derived from skeletal muscle [52]. Taken to-
gether, results from the focused metabolomic study led to
the identification of GLPG0492-specific metabolomic sig-
nature in the hindlimb immobilization model.
Our results are in accordance with several studies in ro-
dents suggesting that muscle atrophy results from a large
increase in proteolysis and an increased oxidative stress.
Unfortunately, little information is available about the in-
fluence of immobilization on markers of muscle protein
breakdown and oxidative stress in humans.
Results of these investigations indicate that GLPG0492,
a non-steroidal SARM, is able to significantly reduce
muscle atrophy in a mouse hindlimb immobilization
model. These protective effects were dose-dependent, and
achieved without significant alteration in serum testoster-
one levels, neither prostate weight (Figure 1C and Table 2).
Moreover, the magnitude of the observed effects on muscle
was comparable to the impact of TP. Muscle anabolic ac-
tivities of SARM and testosterone are well-established in
man [20,21,53,54] and confirm in our model with signifi-
cant increase of normalized prostate weight by TP. The
molecular mechanisms by which AR ligands promote an-
abolism in skeletal muscle are very diverse and are still a
matter of debate (See [54] for review). Androgens are be-
lieved to affect muscle mass by regulating protein synthe-
sis, reducing protein breakdown, modulating myogenic
differentiation and by interfering with key signaling path-
ways involved in skeletal muscle homeostasis [54]. These
effects are mainly mediated by the AR. Chambon andcolleagues demonstrated that the anabolic effects of
androgens are transduced in limb muscles by the AR
expressed in myocytes but also by satellite cells and myofi-
broblasts [55,56]. Moreover, this group reported a signifi-
cant impact of AR gene deletion in myocytes on FCSA in
both fast and intermediary-twitch muscles via a regulation
of IGF-IEa production. In addition, myofibril organization
was found to be disrupted in muscle-specific AR-deficient
mice [55,56]. On the other hand, McLean and coworkers
reported the characterization of AR total knock-out mice
[57]. Male ARKO mice displayed a significantly reduced
skeletal mass which could not be linked to a modulation
of IGF-1 signaling [57]. In this report, transcriptomic
analysis suggested that androgens regulate muscle mass
via the control of muscle commitment and proliferation
[57]. These effects might be explained, at least in part, by
the AR-dependent regulation of ornithine decarboxylase,
which regulates both myoblast proliferation and delays
differentiation as demonstrated by a reduced myogenin
expression [58]. In this model of hindlimb immobilization,
we showed that both TP and GLPG0492 were able to pre-
vent muscle atrophy by down-regulating key transcrip-
tional programs induced by muscle disuse (Figure 3) [4].
Gene expression studies revealed the complex interplay
between AR-dependent signaling pathways (See [50] for
review). Interestingly, we did not observe any regulation
of IGF-1Ea gene expression (Figure 3A). By contrast,
myogenin expression which was significantly increased
following immobilization in line with previous studies
[5,39], was completely suppressed in response to both
GLPG0492 and TP treatments suggesting a potential im-
pact on myoblast differentiation [58]. As previously de-
scribed by Caron and coworkers in the immobilized mouse
model, the induction of the muscle-specific ubiquitin li-
gases, MurF1 and Atrogin-1 is a hallmark of the atrophied
state [6,7,36]. Surprisingly, both GLPG0492 and TP were
found to inhibit immobilization-induced MurF1 but not
Atrogin-1 expression (Figure 3). This selective regulation
of these ubiquitin ligases is reminiscent of the phenotype
of the muscle-specific IKKβ transgenic mice [59]. Over-
expression of IKKβ in the muscle leads to severe muscle
wasting due to MurF1 but not Atrogin-1 gene induction
[59]. The role of NFκB signaling in muscle atrophy was in-
dependently confirmed by Hunter and colleagues [60,61].
Since AR has been shown to negatively interfering with
NFκB signaling pathway [60], it is tempting to speculate
that both GLPG0492 and TP inhibit MurF1 expression via
this mechanism. Further studies are required to fully
Table 3 List of metabolites identified by 1H-NMR analysis of serum samples from intact or immobilized mice after
7 days of treatment with GLPG0492 (10 mg/kg/d) or CTL
Intact Immobilized
Mean SEM CTL GLPG0492
Mean SEM p-value Mean SEM p-value
3-Hydroxybutyrate 239 46 184 25 1207 302 **
Acetate 542 92 460 6 857 124 *
Acetone 19 5 14 3 54 *
Alanine 1977 156 1214 191 ## 1218 45
Asparagine 201 27 124 21 # 127 10
Betaine 142 32 79 32 114 14
Choline 222 24 189 24 251 34
Citrate 773 116 597 63 1076 169 *
Creatine 817 40 839 132 891 97
Dimethylamine 13 1 11 2 10 1
Ethanol 220 31 146 34 181 13
Formate 174 23 155 10 165 27
Fumarate 20 3 12 4 33 7 *
Glucose 29159 4531 23873 3222 33088 2902
Glutamate 337 37 256 37 334 27
Glutamine 1595 239 1019 125 1701 147 *
Glycerol 2638 238 2366 377 3010 469
Glycine 1400 138 893 130 # 1195 102
Histidine 248 27 169 32 218 17
Isobutyrate 57 10 30 4 # 49 6
Isoleucine 393 59 244 37 286 26
Lactate 19808 1196 13878 1491 # 16821 1797
Leucine 486 76 337 52 369 39
Lysine 744 49 792 100 737 81
Malonate 89 13 80 9 98 10
Mannose 106 15 136 28 251 35 *
Methionine 341 34 212 34 # 207 18
O-Acetylcarnitine 45 10 39 5 105 17 **
Phenylalanine 235 20 179 27 176 11
Proline 627 47 337 66 ## 270 41
Pyruvate 480 23 261 32 # 471 65 *
Serine 740 67 449 64 ## 524 29
Succinate 44 9 44 5 85 20
Taurine 2811 217 2860 452 3498 299
Threonine 938 85 636 117 631 34
Trimethylamine N-oxide 200 29 143 41 134 24
Tryptophan 83 7 65 8 52 11
Tyrosine 252 19 171 23 # 168 8
Urocanate 0 0 32 11 # 44 5
Valine 955 136 598 93 610
#p < 0.05, ##p < 0.01 immobilized vs. intact; *p < 0.05, **p < 0.01 GLPG0492-treated vs. CTL; Data are expressed as mean concentrations (μM) ± SEM.
































































































































































Figure 4 GLPG0492 increased plasma metabolite levels linked to TCA cycle, β − oxidation and amino acids metabolism. Metabolic
profiling by 1H-NMR of serum samples from intact or immobilized mice receiving either GLPG0492 (10 mg/kg/day) or vehicle was performed at
day 7. (n = 5 per group; #p < 0.05 Intact vs. Immobilized; *p < 0.05, **p < 0.01 vs. CTL immobilized).
Blanqué et al. BMC Musculoskeletal Disorders 2014, 15:291 Page 10 of 12
http://www.biomedcentral.com/1471-2474/15/291establish this cross-talk in the atrophied muscle. Never-
theless, the inhibition of MurF1 expression suggests that
GLPG0492 and TP prevent muscle atrophy, by slowing-
down protein catabolism.
Interestingly, both treatments failed to regulate markers
of autophagy as demonstrated by the lack of LC3 gene
regulation despite a significant induction following
immobilization for 7 days (Figure 3A). While the role of
TNFα and other cytokines in disuse-induced atrophy
remain unclear [62], we found a strong up-regulation of
IL1β mRNA levels following immobilization in line with
previous results [39]. This induction was completely abol-
ished by treatment with bothTP and GLPG0492 (Figure 3)
suggesting again a potential cross-talk between NFκB and
AR pathways at the transcriptional level. FoxOs have been
identified as the major transcription factors controlling
the balance between protein catabolism and anabolism
[4]. FoxO1 expression is significantly up-regulated in our
model of hindlimb immobilization (Figure 3A) in line
with previous reports [5,8,15]. This induction is also sig-
nificantly repressed by both GLPG0492 and TP treatments
suggesting that AR activation may prevent muscle-atrophy
by negatively interfering with this transcriptional pathway
leading ultimately to a regulation of protein homeostasis in
this tissue. It is noteworthy that FoxO signaling has been
shown to be repressed by PGC-1α [19] whose expression
was found to be increased in response to GLPG0492 and
TP to a lesser extent (Figure 3A). Taken together, theseresults indicate that GLPG0492 minimizes muscle atrophy
by antagonizing the key transcriptional pathways governing
both anabolic and catabolic response.
Results obtained in the focused metabolomic study points
to a modulation of cellular bioenergetic processes linked to
mitochondrial function and perhaps to ketogenesis (Table 3;
Figure 4). These results are quite consistent with the ob-
served up-regulation of PGC-1α gene expression and may
reflect the overall cellular state upon chronic treatment
with GLPG0492 in this hindlimb immobilization model.
In addition, the GLPG0492 metabolomic signature is
somehow comparable to signatures previously related to
moderate exercise in human plasma [50,52]. Further stud-
ies will be required to fully demonstrate that these alter-
ations of the plasma metabolome are mainly reflecting
changes in skeletal muscle physiology. More studies are
still required to investigate the possibility that muscle pro-
tein synthesis could be assessed as a plasma biomarker in
human cachexia. In a recent study, Glover and coworkers
have measured markers of protein breakdown and oxida-
tive stress in muscles of subjects who underwent 14 days
of knee-brace-mediated immobilization. These static mea-
sures of breakdown and oxidative modifications suggested
that a small increase in protein ubiquitination occurs
early (2 days post-immobilization), but is not sustained
during the later phase (after 14 days) of muscle atrophy in
humans, suggesting that these pathways are not playing a
major role in simple disuse-induced atrophic loss of
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the loss of muscle mass results from a reduction in the rate
of protein synthesis. Thus, the normal diurnal fasted-to-
fed cycle of protein balance is disrupted and, as a conse-
quence proteolysis becomes dominant but is not enhanced
[63]. Nevertheless, this metabolomics signature might be
considered as a bona fide biomarker of target engagement
in future clinical studies and may represent an alternative
to the measurement of the muscle fractional synthetic rate
as a mechanistic endpoint which remains quite challen-
ging to implement in phase 1 studies conducted in young
healthy volunteers [64].
Conclusion
GLPG0492 was found as efficacious as TP at reducing
muscle loss in the hindlimb immobilization model.
These effects were achieved without any significant an-
drogenic effects on sexual tissue (Table 1, Figure 1C). Col-
lectively, these results unveil the potential of GLPG0492, a
non-steroidal SARM, as treatment for musculo-skeletal
diseases such as disuse-induced loss of muscle mass
(e.g. coma, paralysis, hospitalization, limb immobilization).
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